Regeneron Acquires 23andMe for $256 Million Amid Bankruptcy
Regeneron Pharmaceuticals is set to acquire 23andMe for $256 million, promising to uphold customer privacy and data protections.
Regeneron Pharmaceuticals to buy 23andMe for over $250 million
World News Group
The rise and fall of 23andMe
Business Insider
Overview
Regeneron Pharmaceuticals has agreed to buy 23andMe for $256 million post-bankruptcy, ensuring uninterrupted operations and strong privacy commitments. 23andMe's asset sale occurred following financial struggles, including a data breach affecting 6.9 million users. Regeneron committed to safeguarding customers' genetic and health information while leveraging this data for drug discovery. The sale, involving a court-appointed overseer to monitor data use, is expected to finalize by the end of Q3 2025. 23andMe expressed satisfaction with the deal, emphasizing continued customer protections and employment for its staff.
Content generated by AI—learn more or report issue.
Get both sides in 5 minutes with our daily newsletter.
Analysis
Left
There are not enough sources from this perspective to provide an analysis.
Center
Regeneron Pharmaceuticals has agreed to acquire 23andMe for $256 million as part of the company's bankruptcy proceedings, with plans to prioritize customer data privacy and comply with existing policies.
The deal raises concerns about the future handling of the genetic data of 15 million customers, especially in light of past data breaches that exposed personal information.
The acquisition will allow Regeneron to enhance its drug discovery processes using the genetic data from 23andMe while assuring customers of their privacy rights.
Right
Regeneron's acquisition of 23andMe marks a strategic opportunity for the pharmaceutical company to enhance its drug development efforts by leveraging consumer genetic data.
The approval process of the acquisition is set to be scrutinized by a court-supervised ombudsman who will assess the implications for consumer privacy.
Regeneron has expressed confidence in maintaining and respecting 23andMe's privacy policies, aiming to resolve concerns while ensuring customer data is protected.
Left
There are not enough sources from this perspective to provide an analysis.
Center
Regeneron Pharmaceuticals has agreed to acquire 23andMe for $256 million as part of the company's bankruptcy proceedings, with plans to prioritize customer data privacy and comply with existing policies.
The deal raises concerns about the future handling of the genetic data of 15 million customers, especially in light of past data breaches that exposed personal information.
The acquisition will allow Regeneron to enhance its drug discovery processes using the genetic data from 23andMe while assuring customers of their privacy rights.
Right
Regeneron's acquisition of 23andMe marks a strategic opportunity for the pharmaceutical company to enhance its drug development efforts by leveraging consumer genetic data.
The approval process of the acquisition is set to be scrutinized by a court-supervised ombudsman who will assess the implications for consumer privacy.
Regeneron has expressed confidence in maintaining and respecting 23andMe's privacy policies, aiming to resolve concerns while ensuring customer data is protected.
Articles (11)
The Guardian·1M·No highlight available for this article.
USA TODAY·1M·No highlight available for this article.
Business Insider·1M·No highlight available for this article.
CBS News·1M·No highlight available for this article.
Fortune·1M·No highlight available for this article.
ARS Technica·1M·No highlight available for this article.
BBC News·1M·No highlight available for this article.
TechCrunch·1M·No highlight available for this article.
World News Group·1M·No highlight available for this article.
Fox Business·1M·No highlight available for this article.
Epoch Times·1M·No highlight available for this article.
FAQ
History
- 1M7 articles